Ερευνητικό υλικό ΕΚΠΑ

The impact of HCG in IVF Treatment: Does it depend on age or on protocol?

Αγγλικά

Objective: to evaluate the effect of the addition of low dose human chorionic gonadotropin (hCG) to human menopausal gonadotropin (HMG) throughout the early follicular phase in controlled ovarian stimulation (COS) conducted with two difference regimens. Gonadotropin-releasing hormone (GnRH) antagonist and short GnRH-agonist protocol were applied in two in vitro fertilization (IVF) clinics. Methods: Clinical study conducted during the period 2014–2016 in two IVF clinics in a cohort of 240 women. In the first group 1 (124 women), a GnRH antagonist protocol with HMG and addition of low dose (100IU/day) h CG was applied. The other group 2 consisted of 116 women who underwent a short GnRH- agonist protocol with HMG and addition of low dose (100 IU/day) h CG. Results: Multiple logistic regression analysis was performed. The group 2 found to be associated with greater number of follicles and oocytes. The pregnancy rates were 12.1% and 26.7% in group 1 and group 2, respectively (p = 0.004). For patients over 40 years, the number of follicles and oocytes retrieved were significant higher in group 2.The pregnancy rate in group 2 was higher than in group 1 (21, 6% vs 5%, p = 0.017). Conclusions: Advanced age women are likely to achievepregnancy using the GnRH Short than GnRH antagonist, when HMG/hCG is used, while HMG–hCG gonadotropins have the same potentialas Recombinant follicle stimulating hormone (rFSH)–hCG used in GnRH short protocol. © 2019 Elsevier Masson SAS

2019

Theofanakis, C.
Athanasiou, V.
Liokari, E.
Stavrou, S.
Sakellariou, M.
Athanassiou, A.-I.
Athanassiou, A.
Drakakis, P.
Loutradis, D.

Journal of Gynecology Obstetrics and Human Reproduction

Elsevier Masson SAS

48

5

341-345

chorionic gonadotropin; follitropin; gonadorelin agonist; gonadorelin antagonist; human menopausal gonadotropin; luteinizing hormone; prolactin; thyrotropin; buserelin; chorionic gonadotropin; fertility promoting agent; ganirelix; gonadorelin; human menopausal gonadotropin, adult; age; Article; body mass; cell stimulation; clinical evaluation; clinical protocol; controlled ovarian stimulation; drug effect; embryo development; embryo transfer; female; female infertility; fertilization; follicular phase; hormone determination; human; in vitro fertilization; intracytoplasmic sperm injection; major clinical study; menstrual cycle; oocyte; oocyte maturation; oocyte retrieval; ovary; ovary follicle; ovary polycystic disease; pregnancy rate; reference value; transvaginal echography; agonists; analogs and derivatives; antagonists and inhibitors; controlled study; ovulation induction; pregnancy; pregnancy rate; randomized controlled trial, Adult; Buserelin; Chorionic Gonadotropin; Female; Fertility Agents, Female; Fertilization in Vitro; Follicular Phase; Gonadotropin-Releasing Hormone; Humans; Menotropins; Oocytes; Ovulation Induction; Pregnancy; Pregnancy Rate

https://doi.org/10.1016/j.jogoh.2019.02.012

10.1016/j.jogoh.2019.02.012

https://pergamos.lib.uoa.gr/uoa/dl/object/3122343